Upgrade to SI Premium - Free Trial

Needham & Company Reiterates Neurocrine (NBIX) at Hold, "Love Execution on Ingrezza" but Cautious on Future Pipeline Readouts

February 14, 2022 5:51 AM
Needham & Company analyst Ami Fadia reiterated a Hold rating on Neurocrine Bio. (NASDAQ: NBIX), following the company's most recent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles